DOI: http://dx.doi.org/10.22516/25007440.81

Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C genotipo 1 - Revisión estructurada

Daniel Pino-Marín, Newar Giraldo, Pedro Amariles

Resumen


Objetivo: establecer y evaluarla relevancia clínica de interacciones medicamentosas en el tratamiento de pacientes con hepatitis C genotipo 1. Método: se realizó una búsqueda en PubMed/MedLine de artículos publicados en inglés y en español, desde el diciembre de 2004 a diciembre de 2014, utilizando los términos Mesh: Hepatitis C AND drug interactions OR herb-drug interactions OR food-drug interactions, de estudios realizados en humanos. Además, la búsqueda se complementó con la revisión, en el mismo período, sobre interacciones de antiretrovirales y hepatitis C en humanos, utilizando los términos Mesh: (Anti-retroviral agents AND Hepatitis C AND drug interactions OR herb-drug interactions OR food-drug interactions). La relevancia clínica de las interacciones medicamentosas se definió y evaluó con base a la probabilidad de ocurrencia y la gravedad de la interacción. Resultados: se identificaron 228 artículos, de los que se pudo acceder al texto completo en 212. De estos, 62 aportaban interacciones, lo que permitió identificar 128 parejas de IM, de las cuales 120 (93,7%) fueron farmacocinéticas y 8 (6,3%) farmacodinámicas. Por su parte, de estas 128 parejas, 2 (1,6%) fueron valoradas de nivel 1: 110 (53,7%) de nivel 2; 16 (7,8%) de nivel 3; y 0 (0%) de nivel 4. Además, se identificaron 78 parejas agrupadas como interacciones con evidencia de ausencia de relevancia clínica. Conclusiones: más del 90% de las interacciones medicamentosas de relevancia clínica son farmacocinéticas asociadas a cambios del metabolismo hepático, el telaprevir fue el medicamento con mayor número de interacciones. 


Palabras clave


Interacciones medicamentosas; antirretrovirales; hepatitis C; boceprevir; telaprevir

Texto completo:

PDF

Referencias


Izquierdo-García E, Escobar-Rodríguez I. [Systematic review of new protease inhibitors interactions: telaprevir and boceprevir]. Farm Hosp. 2012;36:469-82.

Morillo Verdugo R, Romero Gómez M. [A new therapeutic scene in the treatment of the chronic hepatitis for virus C]. Farm Hosp. 2012;36:466-8.

Mallolas Masferrer J, Martínez-Rebollar M, Laguno Centeno M. [Treatment of hepatitis C virus in HIV-positive patients]. Gastroenterol Hepatol. 2011;34:558-67

Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-8.

Valencia ME, Moreno V. [Coinfection with HIV and HCV: abacavir and ribavirine, why not?]. Rev Clin Esp. 2012;212:26-30.

Soriano V, Martin-Carbonero L, Vispo E, Labarga P, Barreiro P. [Human immunodeficiency virus infection and viral hepatitis]. Enferm Infecc Microbiol Clin. 2011;29:691-701.

Amariles P, Giraldo NA, Faus MJ. Interacciones Medicamentosas: aproximación para Establecer y evaluar su relevancia clínica. Med Clin Barc 2007; 129:27-35.

Giraldo NA, Amariles P, Gutiérrez FJ, Monsalbe M, Faus MJ. Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en pacientes infectados con virus de la inmunodeficiencia humana: actualización 2009. Farm Hosp 2010;34:90-93

Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013;6:249-69.

Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS. 2011;6:514-26.

Rodríguez-Torres M. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient. Expert Rev Anti Infect Ther. 2012;10:1117-28.

Varun Garg, Gurudatt Chandorkar, Yijun Yang, Nathalie

Adda,et al :The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers, Br J Clin Pharmacol 2012;75:431–39

Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O’Mara E, Youngberg SP, Wagner JA, Butterton JR. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir- boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56:718-26.

Ceballos ME. [Considerations in first line antiretroviral selection for adults]. Rev Chilena Infectol. 2013;30:522-37.

Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012;55:1620-8.

Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int. 2013;33 Suppl 1:63-7.

Schwarze-Zander C, Rockstroh JK. HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients? AIDS. 201210;26:1845-6.

Tseng A, Foisy M, Hughes CA, Kelly D, Chan S, Dayneka N, et al. Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines. Can J Hosp Pharm. 2012;65:125-45.

Rodríguez-Torres M. Focus on drug interactions: the challenge of treating hepatitis C virus infection with directacting antiviral drugs in the HIV-positive patient. Curr Opin Infect Dis. 2013;26:50-7.

Deeks D. E. Darunavir: A Review of Its Use in the Management of HIV-1 Infection, Drugs (2014) 74:99–125

Lauren J Gleason, Amneris E Luque, Krupa Shah; Polypharmacy in the HIV-infected older adult population Clinical Interventions in Aging 2013:8 749–763

M. Rabanal Tornero; Terapia de sustitución con metadona: interacciones farmacológicas y no farmacológicas; Butlletí d’informació terapéutica. Generalitat de Catalunya, Departament de salut, Vol 24, num 6. 2013.

Vanpouille C, Lisco A, Introini A, Grivel JC, Munawwar A, Merbah M, et al.Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin. Antimicrob Agents Chemother. 2012;56:2604-11.

Mauss S, Klinker H. Drug-drug interactions in the treatment of HCV among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:125-8.

Ingiliz P, Rockstroh JK. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int. 2012;32:1194-9.

Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792-800.

Teixeira R, Nascimento Yde A, Crespo D. Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Braz J Infect Dis. 2013;17:194-204.

Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596-606.

Berenguer Berenguer J, González-García J. [Pharmacokinetic interactions of telaprevir with other drugs]. Enferm Infecc Microbiol Clin. 2013;31 Suppl 3:37-48.

Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis. 2013;30:45 Suppl 5:S343-8.

Sockalingam S, Tseng A, Giguere P, Wong D. Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol. 201314;13:86.

Barritt AS 4th, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus Gastroenterology. 2012;142:1314-1323.

Kozielewicz D, Halota W, Dybowska D. Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors. Przegl Epidemiol. 2013;67:623- 8,713-6.

Lamers MH, Broekman MM, Boucher CA, Brouwer JT, Burger DM, van Hoek B, Hoepelman AI, de Knegt RJ, Reesink HW, Drenth JP et al. Treatment of hepatitis C monoinfection in adults--Dutch national guidelines. Neth J Med. 2013;71:377-85.

Sulkowski MS. HCV therapy in HIV-infected patients. Liver Int. 2013;33 Suppl 1:63-7.

Jennings CL, Sherman KE. Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Curr HIV/ AIDS Rep. 2012;9(3):231-7.

Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2012;20:48-60.

Puoti M, Rossotti R, Travi G, Panzeri C, Morreale M, Chiari E, et al. Optimizing treatment in HIV/HCV coinfection. Dig Liver Dis. 2013;45 Suppl 5:S355-62.

Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27:36-45.

Vachon ML, Dieterich DT. The HIV/HCV-coinfected patient and new treatment options. Clin Liver Dis. 2011;15:585-96.

Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012;26:205-10.

Bruno R, Fagiuoli S, Sacchi P. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients? Expert Rev Anti Infect Ther. 2011;9:699-701.

Sulkowski MS. Hepatitis C virus-human immunodeficiency virus coinfection. Liver Int. 2012;32 Suppl 1:129-34.

Kim JJ, Culley CM, Mohammad RA. Telaprevir: an oral protease inhibitor for hepatitis C virus infection. Am J Health Syst Pharm. 20121;69(1):19-33.

Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57:1379-90.

Chaparro M, Trapero-Marugán M, Moreno-Otero R, Gisbert JP. Azathioprine plus ribavirin treatment and pancytopenia. Aliment Pharmacol Ther. 2009;30:962-3.

Sockalingam S, Tseng A, Giguere P, Wong D. Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol. 2013;14;13-86.

Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, Viciana P, Espinosa N, Castillo-Ferrando JR, Lopez-Cortes LF. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. Clin Infect Dis. 2014;58:268-73.

O’Leary JG, McKenna GJ, Klintmalm GB, Davis GL. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl. 2013;19:463-5.

Lê MP, Gervais A, Le Beller C, Long K, Larrouy L, Papy E, Mal H, et al. Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir. J Antimicrob Chemother. 2013;68:1208-9.

Luetkemeyer AF, Havlir DV, Currier JS. CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy. Top Antivir Med. 2013;21:62-74.

Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drugdrug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815-31.

Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology. 2011;54:3-5.

Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531-48.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 2012;18:1464-70.

Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20-7.

Hulskotte E, Gupta S, Xuan F, van Zutven M, O’Mara E, Feng HP, Wagner J, Butterton J. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012;56:1622-30.

Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J Clin Pharmacol. 2007;47:604-12.

Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch

MN. Effects of pegylated interferon alfa-2b on the pharmacokinetic

and pharmacodynamic properties of methadone:

a prospective, nonrandomized, crossover study in patients

coinfected with hepatitis C and HIV receiving methadone

maintenance treatment. Clin Ther. 2007;29:131-8.

Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse. 2006;41:1395-463.

Rodríguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther. 2013;11:1269-79.

Fowell AJ, Nash KL. Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther. 2010;27(8):512-22.

Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother. 2010;65(6):1079-85.

Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Bräu N, Hatzakis A, Pol S, Rockstroh J. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-89.

Lai AR, Tashima KT, Taylor LE. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus. AIDS Patient Care STDS. 2006;20:678-92.

Nelson M, Lipman M. Management of advanced HIV disease in patients with tuberculosis or hepatitis co-infection. Int J Clin Pract. 2006;60:976-83.

Soriano V, Nuñez M, Garcia-Samaniego J, Labarga P, Simarro N, Martín-Carbonero L, Romero M, Ramos B, Barreiro P. Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less. Infect Disord Drug Targets. 2006;6:57-88.

Park JS, Saraf N, Dieterich DT. HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep. 2006;8:67-74.

Sherman KE. Treatment of hepatitis C virus and human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol. 2005;3:S118-21.

Mallolas Masferrer J, Martínez-Rebollar M, Laguno Centeno M. [Treatment of hepatitis C virus in HIV-positive patients]. Gastroenterol Hepatol. 2011;34:558-67.

Miró JM, Torre-Cisnero J, Moreno A, Tuset M, Quereda C, Laguno M, et al. [GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. Enferm Infecc Microbiol Clin. 2005;23:353-62.

Nogueira JB, Sena LC, Quintans Jde S, Almeida JR, França AV, Júnior LJ. Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: a small audit. J Pharm Pract. 2012;25:85-8.

Simón-Talero M, Buti M, Esteban R. Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction? J Viral Hepat. 2012;19:14-7.

Ramanathan S, Cheng A, Mittan A, Ebrahimi R, Kearney BP. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. J Clin Pharmacol. 2006;46:559-66.

Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J

Gastroenterol Hepatol. 2008;23:1000-8.

Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006;20:273-82.

Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52:981-94

Shah BM, Schafer JJ, Desimone JA Jr. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2014;34:506-20.

González-Colominas E, Solà R, Barrantes-González M, Salas E. [Prevalence of potential interactions between antiretroviral therapy and boceprevir or telaprevir in human immunodeficiency virus-hepatitis C virus coinfected patients]. Enferm Infecc Microbiol Clin. 2013;31:350-1.

Franco D, Henao Y, Monsalve M, Gutiérrez F, Hincapie J, Amariles P. [Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review]. Farm Hosp. 2013;37:539-57.

Kasserra C, Hughes E, Treitel M, et al. Clinical pharmacology of boceprevir: metabolism, excretion, and drugdrug interactions [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA.

Garg V, Luo X, McNair L, et al. Low-dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers [abstract 629]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA.

Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S, Bani-Sadr F, Izopet J, Garraffo R, Peytavin G; ANRS CO-13 HEPAVIH Study Group. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS. 2012;26:2193-9.

Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for directacting antivirals. Gastroenterology. 2012;142:1324-1334.e3

Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11:179-85.

Tuma P, Vispo E, Barreiro P, Soriano V. [Role of tenofovir in HIV and hepatitis C virus coinfection]. Enferm Infecc Microbiol Clin. 2008;26 Suppl 8:31-7.

Sherman KE. New paradigms in the management of hepatitis C virus co-infections. Nat Clin Pract Gastroenterol Hepatol. 2007;4 Suppl 1:S10-6.

Ruiz-Sancho A, Soriano V. [HIV and HCV coinfection]. Enferm Infecc Microbiol Clin. 2006;24:335-45; quiz 346.

Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med. 199927;107:79S-84S.


Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2017 Revista Colombiana de Gastroenterología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN versión impresa 0120-9957

ISSN versión en línea 2500-7440

  Licencia de Creative Commons
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.